The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients
A subset of hospitalized COVID-19 patients, particularly the aged and those with comorbidities, develop the most severe form of the disease, characterized by acute respiratory disease syndrome (ARDS), coincident with experiencing a "cytokine storm." Here, we demonstrate that cytokines which activate the NF-κB pathway can induce activin A. Patients with elevated activin A, activin B, and FLRG at hospital admission were associated with the most severe outcomes of COVID-19, including the requirement for mechanical ventilation, and all-cause mortality. A prior study showed that activin A could decrease viral load, which indicated there might be a risk to giving COVID-19 patients an inhibitor of activin. To evaluate this, the role for activin A was examined in a hamster model of SARS-CoV-2 infection, via blockade of activin A signaling. The hamster model demonstrated that use of an anti-activin A antibody did not worsen the disease and there was no evidence for increase in lung viral load and pathology. The study indicates blockade of activin signaling may be beneficial in treating COVID-19 patients experiencing ARDS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Molecular and cellular biology - 42(2022), 1 vom: 20. Jan., Seite e0046721 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McAleavy, Megan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.02.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/MCB.00467-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332618986 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332618986 | ||
| 003 | DE-627 | ||
| 005 | 20231225215934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/MCB.00467-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332618986 | ||
| 035 | |a (NLM)34723652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McAleavy, Megan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A subset of hospitalized COVID-19 patients, particularly the aged and those with comorbidities, develop the most severe form of the disease, characterized by acute respiratory disease syndrome (ARDS), coincident with experiencing a "cytokine storm." Here, we demonstrate that cytokines which activate the NF-κB pathway can induce activin A. Patients with elevated activin A, activin B, and FLRG at hospital admission were associated with the most severe outcomes of COVID-19, including the requirement for mechanical ventilation, and all-cause mortality. A prior study showed that activin A could decrease viral load, which indicated there might be a risk to giving COVID-19 patients an inhibitor of activin. To evaluate this, the role for activin A was examined in a hamster model of SARS-CoV-2 infection, via blockade of activin A signaling. The hamster model demonstrated that use of an anti-activin A antibody did not worsen the disease and there was no evidence for increase in lung viral load and pathology. The study indicates blockade of activin signaling may be beneficial in treating COVID-19 patients experiencing ARDS | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a FLRG | |
| 650 | 4 | |a FSTL3 | |
| 650 | 4 | |a SARS-Cov-2 | |
| 650 | 4 | |a activin A | |
| 650 | 4 | |a activin B | |
| 650 | 4 | |a acute respiratory disease syndrome | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Follistatin-Related Proteins |2 NLM | |
| 650 | 7 | |a activin A |2 NLM | |
| 650 | 7 | |a activin B |2 NLM | |
| 650 | 7 | |a Activins |2 NLM | |
| 650 | 7 | |a 104625-48-1 |2 NLM | |
| 650 | 7 | |a sarilumab |2 NLM | |
| 650 | 7 | |a NU90V55F8I |2 NLM | |
| 700 | 1 | |a Zhang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Ehmann, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jianing |e verfasserin |4 aut | |
| 700 | 1 | |a Wipperman, Matthew F |e verfasserin |4 aut | |
| 700 | 1 | |a Ajithdoss, Dharani |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Wakai, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Simonson, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Gadi, Abhilash |e verfasserin |4 aut | |
| 700 | 1 | |a Oyejide, Adelekan |e verfasserin |4 aut | |
| 700 | 1 | |a Hamon, Sara C |e verfasserin |4 aut | |
| 700 | 1 | |a Boyapati, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Morton, Lori G |e verfasserin |4 aut | |
| 700 | 1 | |a Shavlakadze, Tea |e verfasserin |4 aut | |
| 700 | 1 | |a Kyratsous, Christos A |e verfasserin |4 aut | |
| 700 | 1 | |a Glass, David J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular and cellular biology |d 1981 |g 42(2022), 1 vom: 20. Jan., Seite e0046721 |w (DE-627)NLM012604763 |x 1098-5549 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:1 |g day:20 |g month:01 |g pages:e0046721 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/MCB.00467-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 1 |b 20 |c 01 |h e0046721 | ||